The incidence cases of PCED in the US is
Comprehensive insight on patient segmentation based on age, sex, Settings (Acute & Refractory cases), Risk factors (Ocular herpes sim-plex, epithelial and stromal keratitis, scarring, tissue destruction, neovascularization, and glaucoma) Signs & Symptoms, etiology (defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and other ) Clinical Manifestations, Treatment types (Aggressive lubrication, Punctal occlusion, Bandage soft contact lens, Pressure patching, Amniotic membrane grafting, Autologous serum, Scleral contact lenses, Topical and systemic antibiotics, anti-inflammatory agents and Others) has been provided into the epidemiology section of the PCED and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are few drug candidates/biologicals are in different Phase (Phase I, II & III) stages of development. Key companies are Kala Pharmaceuticals, Noveome Biotherapeutics, Santen Pharmaceutical, OcuNexus Therapeutics, Zhaoke Ophthalmology Pharmaceutical Ltd. And Eyevance Pharmaceuticals. Autologous adipose-derived mesenchymal stem cells (MSCs) have recently been introduced as a potential breakthrough therapy for PED and stromal ulceration. These cells are multipotent and therefore have the capacity to differentiate into any human cell type. Thymosin beta 4 is a synthetically produced copy of a 43-amino acid peptide that has been demonstrated to promote corneal wound re-epithelialization, diminish inflammation, and inhibit apoptosis. Looking at the current clinical development and assets progress card, it would really be a great opportunity for the pharmaceutical company to build products around the treatment of PCED specifically for refractory patients.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,